To study comparative effectiveness of carvedilol and bisoprolol on the levels of neurohumoral factors in patients with chronic heart failure (CHF). Methods. Examined 92 patients with postinfarction cardiosclerosis, complicated by CHF. Patients having myocardial infarction within 6 months – 3 years were randomly assigned to re¬ceive bisoprolol or carvedilol. The patients were divided into two groups: 1 - 44 patients treated on standard therapy and BAB, which has α1-, β1-and β2 - blocking properties - carvedilol; 2 - 48 patients treated on standard therapy – and highly selective BAB - bisoprolol. BAB titration was performed from 3,125 to 25-50 mg/day assigned dose for - carvedilol and 1.25 to 10 mg/day assigned dose for - bisoprolol. Results. Patients with FC II had increased amount of BNP by 181,8% (p <0,001), and patients with FC III by 319.5% (p <0,001) compared with the control group. There was also a significant increase of aldosterone in both groups of patients: in patients with FC II, level of aldosterone increased by 36.8% (p<0,001) compared with the control group. In patients with FC III it was 66.4% (p<0,001). Aldosterone levels increased by 1,3-fold in FC II and 1.6-fold in FC III. Conclusion. Six-month carvedilol therapy of CHF significantly decreased BNP and aldosterone in patients with both FC II and III. Six-month bisoprolol therapy of CHF also leads to a significant decrease in BNP and
Loading....